|
市場調查報告書
非專利藥品的侵蝕：2008年
SPECIAL REPORT: Patterns of Generic Erosion: An International Chartbook, 2008
|
本報告已在2011年12月27日停止出版。
更改為出版
Special Report: Patterns of Generic Erosion: An International Chartbook
出版日期 : 2011年12月
商品編碼: 227314
本報告書內容包括：非專利藥品概要及與品牌藥的競爭、對品牌藥市場的侵蝕、藥品產業的未來預測、美國、法國、德國、義大利、西班牙、英國及日本等各國動向總結。內容綱要摘記如下：
實施概要
概要
方法論
美國
法國
德國
義大利
西班牙
英國
日本
國際比較
藥品產業的未來預測及影響
圖表
Abstract
Introduction
Healthcare payers around the world are desperate to fi nd ways to contain
pharmaceutical expenditures without compromising the quality of the services
they provide This cost-conscious climate has stimulated vigorous growth in the
generics market: from 2003 through 2007, sales of generics in eight leading
pharmaceutical markets grew by an average of 101% per year - double the rate
of growth for nongenerics Manufacturers of branded drugs that face patent
expiration need to be familiar with patterns of generic erosion in the major
markets - in particular, the impact of generics competition on pricing and
market share trends The 45 fi gures and tables in this chartbook - a
substantially expanded update of our 2007 report - provide this critical
analysis
Get the Answers You Need to Shape Your Strategy
- The United States has the world' s largest and reputedly most aggressive
generics market What effect has generics competition had on brand and generics
prices? How rapid is generic erosion of branded drugs' market share? What are
US payers doing to promote greater use of generics?
- Northern European markets are highly mature and characterized by
aggressive generics erosion How rapid is price erosion in Germany? How large
are price differentials between generics and branded drugs in Germany? How has
the United Kingdom' s strong generic prescribing culture infl uenced the rate
of generic erosion in that country?
- Southern European generics markets have the reputation of being highly
conservative What radical changes are transforming the French generics market?
How have Italy' s low prices for branded drugs infl uenced generic erosion?
What measures has the Spanish government taken to stimulate greater use of
generics?
- Japan' s generics market has remained largely underdeveloped despite the
government' s attempts to stimulate greater use of generics How do
manufacturers of branded drugs respond to generics competition in a market
that routinely cuts prices every other year? What market share do brands
retain after three years of generics competition? What is the Japanese
government
- doing to boost the generics market?
Scope
- General environment: penetration of generics; measures implemented by
governments and other
- payers to stimulate the use of generics; acceptance of generics
- Pricing trends: impact of generics competition on the brand,
weighted-average generic, and lowestpriced
- generic prices over time
- Market trends: generics' erosion of branded drugs share of sales and
dispensed units of 32 select
- off-patent compounds
- Outlook and implications for the pharmaceutical industry: payer strategies
to stimulate the use
- of generics; impact of reference pricing; prospects for biosimilars;
defense strategies against generics
- competition; outlook for new drugs
Mentioned in This Spectrum Report
Drugs
- Alendronic acid
- Azithromycin
- Carvedilol
- Cefpodoxime proxetil
- Ceftazidime
- Citalopram
- Clarithromycin
- Epirubicin
- Finasteride
- Fluconazole
- Flumazenil
- Fluticasone
- Formoterol
- Gabapentin
- Glimepiride
- Itraconazole
- Lamotrigine
- Lansoprazole
- Lisinopril
- Meloxicam
- Mirtazapine
- Mitoxantrone
- Omeprazole
- Ondansetron
- Paclitaxel
- Pergolide
- Pravastatin
- Quinapril
- Sertraline
- Simvastatin
- Tamsulosin
- Terbinafi ne
- Zolpidem
Companies
- Abbott Laboratories
- Almirall
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo,
- Eli Lilly
- Forest Laboratories
- GlaxoSmithKline
- Lundbeck,
- Merck & Co
- Novartis
- Ortho-McNeil-Janssen Pharmaceuticals
- Pfi zer
- Roche
- Sanofi -Aventis
- Schering Plough
- Takeda
- Wyeth
Table of Contents
Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Methodology
- United States
- General Environment
- Pricing Trends
- Market Share Trends
- France
- General Environment
- Pricing Trends
- Market Share Trends
- Germany
- General Environment
- Pricing Trends
- Market Share Trends
- Italy
- General Environment
- Pricing Trends
- Market Share Trends
- Spain
- General Environment
- Pricing Trends
- Market Share Trends
- United Kingdom
- General Environment
- Pricing Trends
- Market Share Trends
- Japan
- General Environment
- Pricing Trends
- Market Share Trends
- International Comparisons
- Pricing Trends
- Market Share Trends
- Outlook and Implications for the Pharmaceutical Industry
Tables
- 1 Off-Patent Compounds Covered in This Report
- 2 Launch Dates for Generics Covered in This Report
- 3 Exchange Rates Relative to the US Dollar, 2002-2007
- 4 United States: Pricing Trends for Select Off-Patent Compounds, by Year
- 5 United States: Branded Drugs' Share of Total Sales of Select Off-Patent
Compounds, by Quarter
- 6 United States: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
- 7 France: Pricing Trends for Select Off-Patent Compounds, by Year
- 8 France: Branded Drugs' Share of Total Sales of Select Off-Patent
Compounds, by Quarter
- 9 France: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
- 10 Germany: Average Percentage Price Difference Between Median Prices of
Generic and Branded Versions of Off-Patent Drugs, 1981-2006
- 11 Germany: Pricing Trends for Select Off-Patent Compounds, by Year
- 12 Germany: Branded Drugs' Share of Total Sales of Select Off-Patent
Compounds, by Quarter
- 13 Germany: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
- 14 Italy: Pricing Trends for Select Off-Patent Compounds, by Year
- 15 Italy: Branded Drugs' Share of Total Sales of Select Off-Patent
Compounds, by Quarter
- 16 Italy: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
- 17 Spain: Pricing Trends for Select Off-Patent Compounds, by Year
- 18 Spain: Branded Drugs' Share of Total Sales of Select Off-Patent
Compounds, by Quarter
- 19 Spain: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
- 20 United Kingdom: Pricing Trends for Select Off-Patent Compounds, by Year
- 21 United Kingdom: Branded Drugs' Share of Total Sales of Select
Off-Patent Compounds, by Quarter
- 22 United Kingdom: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
- 23 Japan: Pricing Trends for Select Off-Patent Compounds, by Year
- 24 Japan: Branded Drugs' Share of Total Sales of Select Off-Patent
Compounds, by Quarter
- 25 Japan: Branded Drugs' Share of Total Dispensed Units of Select
Off-Patent Compounds, by Quarter
Figures
- 1 United States: Average Pricing Trends for Off-Patent Compounds
- 2 United States: Average Brand Market and Unit-Volume Share for Off-Patent
Compounds
- 3 France: Generics Penetration Rates for Select Compounds, December 2007
and April 2008
- 4 France: Average Pricing Trends for Off-Patent Compounds
- 5 France: Average Brand Market and Unit-Volume Share for Off-Patent
Compounds
- 6 Germany: Average Pricing Trends for Off-Patent Compounds
- 7 Germany: Average Brand Market and Unit-Volume Share for Off-Patent
Compounds
- 8 Italy: Average Pricing Trends for Off-Patent Compounds
- 9 Italy: Average Brand Market and Unit-Volume Share for Off-Patent
Compounds
- 10 Spain: Average Pricing Trends for Off-Patent Compounds
- 11 Spain: Average Brand Market and Unit-Volume Share for Off-Patent
Compounds
- 12 United Kingdom: Average Pricing Trends for Off-Patent Compounds
- 13 United Kingdom: Average Brand Market and Unit-Volume Share for
Off-Patent Compounds
- 14 Japan: Average Pricing Trends for Off-Patent Compounds
- 15 Japan: Average Brand Market and Unit-Volume Share for Off-Patent
Compounds
- 16 All Markets: Average Brand Pricing Trends for Off-Patent Compounds
- 17 All Markets: Average Weighted-Average Generic Pricing Trends for
Off-Patent Compounds
- 18 All Markets: Average Lowest-Priced Generic Pricing Trends for
Off-Patent Compounds
- 19 All Markets: Average Brand Market Share for Off-Patent Compounds
- 20 All Markets: Average Brand Unit-Volume Share for Off-Patent Compounds
|
